Retrospective Analysis of Pyrotinib-Based Therapy for Metastatic Breast Cancer: Promising Efficacy in Combination with Trastuzumab

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca-a Can J Clini. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Pestalozzi BC, Zahrieh D, Price KN, et al. Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol. 2006;17(6):935–944. doi:10.1093/annonc/mdl064
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Clark GM, Wong SG, et al. Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene. Science. 1987;235(4785):177–182. doi:10.1126/science.3798106
   PubMed Web of Science ®Google Scholar
• Swain SM, Miles D, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, Phase 3 study. Lancet Oncol. 2020;21(4):519–530. doi:10.1016/s1470-2045(19)30863-0
   PubMed Web of Science ®Google Scholar
• Nahta R, Yu DH, Hung MC, Hortobagyi GN, Esteva FJ. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nature Clin Pract Oncol. 2006;3(5):269–280. doi:10.1038/ncponc0509
   PubMedGoogle Scholar
• Xuhong JC, Qi XW, Zhang Y, Jiang J. Mechanism, safety and efficacy of three tyrosine kinase inhibitors lapatinib, neratinib and pyrotinib in HER2-positive breast cancer. Am J Canc Res. 2019;9(10):2103–2119.
   PubMed Web of Science ®Google Scholar
• Guan XW, Ma F, Li Q, et al. Pyrotinib plus capecitabine could significantly improve overall survival in HER2-positive metastatic breast cancer. Sig Trans Target Therap. 2023;8(1). doi:10.1038/s41392-023-01322-w
   Web of Science ®Google Scholar
• Hu W, Yang J, Zhang Z, Xu D, Li N. Pyrotinib for HER2-positive metastatic breast cancer: a systematic review and meta-analysis. Transl Canc Res. 2023;12(2):247–256. doi:10.21037/tcr-22-1746
   PubMed Web of Science ®Google Scholar
• Lin NU, Borges V, Anders C, et al. Intracranial efficacy and survival with Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial. J Clin Oncol. 2020;38(23):2610–+. doi:10.1200/jco.20.00775
   PubMed Web of Science ®Google Scholar
• Blackwell KL, Burstein HJ, Storniolo AM, et al. Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer. J Clin Oncol. 2010;28(7):1124–1130. doi:10.1200/jco.2008.21.4437
   PubMed Web of Science ®Google Scholar
• Ma F, Yan M, Li W, et al. Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial. BMJ. 2023;383. doi:10.1136/bmj-2023-076065
   Google Scholar
• Wang X, Liu P, Fenghua LU, Tan Q. Evaluation of Critical Quality Attributes of an Anti-HER2 Humanized Monoclonal Antibody Drug. Chin Pharm J. 2015;50(12):1054–1061.
   Google Scholar
• Cao J, Teng Y, Li HP, et al. Pyrotinib plus capecitabine for trastuzumab-resistant, HER2-positive advanced breast cancer (PICTURE): a single-arm, multicenter Phase 2 trial. BMC Med. 2023;21(1). doi:10.1186/s12916-023-02999-0
   Web of Science ®Google Scholar
• Xu BH, Yan M, Ma F, et al. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22(3):351–360. doi:10.1016/s1470-2045(20)30702-6
   PubMed Web of Science ®Google Scholar
• Blackwell KL, Zaman K, Qin SK, et al. Neratinib in combination with Trastuzumab for the treatment of patients with advanced HER2-positive Breast Cancer: A Phase I/II Study. Clinic Breast Canc. 2019;19(2):97–+. doi:10.1016/j.clbc.2018.12.011
   PubMed Web of Science ®Google Scholar
• Baselga J, Cortés J, Kim SB, et al. Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer. N Engl J Med. 2012;366(2):109–119. doi:10.1056/NEJMoa1113216
   PubMed Web of Science ®Google Scholar
• Oshima Y, Tanaka H, Murakami H, et al. Lapatinib sensitivities of two novel trastuzumab-resistant HER2 gene-amplified gastric cancer cell lines. Gastric Cancer. 2014;17(3):450–462. doi:10.1007/s10120-013-0290-6
   PubMed Web of Science ®Google Scholar
• Scaltriti M, Rojo F, Ocaña A, et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Nation Canc Inst. 2007;99(8):628–638. doi:10.1093/jnci/djk134
   PubMed Web of Science ®Google Scholar
• Extra JM, Antoine EC, Vincent-Salomon A, et al. Efficacy of Trastuzumab in Routine Clinical Practice and After Progression for Metastatic Breast Cancer Patients: the Observational Hermine Study. Oncologist. 2010;15(8):799–809. doi:10.1634/theoncologist.2009-0029
   PubMed Web of Science ®Google Scholar
• Dong C, Wu J, Chen Y, Nie J, Chen C. Activation of PI3K/AKT/mTOR pathway causes drug resistance in Breast Cancer. Front Pharm. 2021;12:628690. doi:10.3389/fphar.2021.628690
   PubMed Web of Science ®Google Scholar
• Willman M, Willman J, Lucke-Wold B. Endocrine resistant breast cancer: brain metastasis. Explor Target Antitumor Ther. 2022;3(2):240–251. doi:10.37349/etat.2022.00081
   PubMedGoogle Scholar
• Giuliano M, Trivedi MV, Schiff R. Bidirectional crosstalk between the estrogen receptor and human epidermal growth factor receptor 2 signaling pathways in Breast Cancer: Molecular basis and clinical implications. Breast Care. 2013;8(4):256–262. doi:10.1159/000354253
   PubMed Web of Science ®Google Scholar
• Kwon YS, Nam KS, Kim S. Tamoxifen overcomes the trastuzumab-resistance of SK-BR-3 tumorspheres by targeting crosstalk between cytoplasmic estrogen receptor α and the EGFR/HER2 signaling pathway. Biochem Pharm. 2021;190:114635. doi:10.1016/j.bcp.2021.114635
   PubMed Web of Science ®Google Scholar
• Verma S, Miles D, Gianni L, et al. Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer. N Engl J Med. 2012;367(19):1783–1791. doi:10.1056/NEJMoa1209124
   PubMed Web of Science ®Google Scholar
• Cortés J, Kim SB, Chung WP, et al. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. N Engl J Med. 2022;386(12):1143–1154. doi:10.1056/NEJMoa2115022
   PubMed Web of Science ®Google Scholar
• Zhao J, Cai Y, Ding L, et al. Inetetamab combined with pyrotinib and Chemotherapy in Pretreated Patients with HER2-positive metastatic breast cancer, a single arm, multicenter phase II clinical trial. Cancer Res. 2023;83(5): 5
   Web of Science ®Google Scholar
• Cai S, Chen H, Chen X, Zhang J. Clinical efficacy observation of multi-line therapy of inetetamab combined with pyrotinib(China double target) in patients with Her2 positive breast cancer. J Chong Medl Univ. 2022;47(12):1479–1484.
   Google Scholar
• Bachelot T, Romieu G, Campone M, et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol. 2013;14(1):64–71. doi:10.1016/s1470-2045(12)70432-1
   PubMed Web of Science ®Google Scholar
• Yan M, Ouyang Q, Sun T, et al. Pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer and brain metastases: 3-year follow-up results from the phase 2 PERMEATE trial. J Clin Oncol. 2023;41(16):1048. doi:10.1200/JCO.2023.41.16_suppl.1048
   Web of Science ®Google Scholar
• Taskar KS, Rudraraju V, Mittapalli RK, et al. Lapatinib distribution in HER2 overexpressing experimental brain metastases of Breast Cancer. Pharm Res. 2012;29(3):770–781. doi:10.1007/s11095-011-0601-8
   PubMed Web of Science ®Google Scholar
• Jiang ZF, Yan M, Hu XC, et al. Pyrotinib combined with capecitabine in women with HER2+metastatic breast cancer previously treated with trastuzumab and taxanes: a randomized Phase III study. J Clin Oncol. 2019;37(15):1001. doi:10.1200/JCO.2019.37.15_suppl.1001
   PubMed Web of Science ®Google Scholar
• Fang C, Wen J, Kang M, et al. Incidence and management of pyrotinib-associated diarrhea in HER2-positive advanced breast cancer patients. Annals Palliative Med. 2022;11(1):210–216. doi:10.21037/apm-21-3978
   PubMed Web of Science ®Google Scholar